About Chris Dimitropoulos
Chris Dimitropoulos is a managing director, alpha wave global at Moonwalk Biosciences.
Form D filings also name Chris Dimitropoulos as a director at Apnimed, Biolinq, HistoSonics and Alto Neuroscience.
Chris Dimitropoulos reports to the SEC as a director of 1 public company: Apnimed (APMD).
Chris Dimitropoulos first appears on SEC filings in 2022.
Experience
This experience comes from Chris Dimitropoulos's profile and from SEC filings. For roles taken from filings, the years are when the filings name Chris Dimitropoulos in the role, so the role may have started earlier or lasted longer.
AL
Alpha Wave Global, LP Current
Managing Director, Biotechnology Investments (Private & Public)
2021 – Present
Moonwalk Biosciences, Inc.
Managing Director, Alpha Wave Global
2026 · South San Francisco, CA
Develops fat-tissue-targeted therapies for people with obesity and cardiometabolic diseases.
Apnimed, Inc.
Director
2022 – 2026 · Public company (APMD)
Develops oral medicines for people with sleep apnea and other sleep-related breathing diseases.
IT
Inexos Therapeutics
CEO/Co-Founder
2019 – 2021
JP
J. Goldman & Co., L.P.
Portfolio Manager
2016 – 2019
MP
Millennium Partners
Portfolio Manager - Carve-Out
2012 – 2015
AG
Astor Group
VP
2009 – 2012
CI
Citadel
Hedge Fund: Biotech Equities Analyst
2007 – 2009
JM
J.P. Morgan
Biotech Equities Associate Analyst
2005 – 2007
Key Colleagues at Startups
The people Chris Dimitropoulos works with at each company, as listed on that company's latest Form D.
Moonwalk Biosciences, Inc. · Form D, Sep 14, 2026
John Liles
VP Biology & Translational Science
AJ
Arash Jamshidi
President and director
AA
Alexander Aravanis
Executive officer and director
Justin Valley
Co-Founder, Chief Platform Officer
SD
Stephen Djedjos
Executive officer
PB
Paul Burton
Director
EC
Elaine Cheung
Executive officer
Apnimed, Inc. · Form D, Mar 27, 2026
LM
Lawrence Miller
Executive officer and director
Paul Fonteyne
Director
DM
Dennis Molnar
Executive officer
Barry Wohl
Chief Business Officer
JA
Joseph Avellone
Director
FB
Francois Beaubien
Director
KL
Kevin Lind
Chief Executive Officer and director
IC
Isaac Cheng
Director
GS
Gary Sender
Director
RB
Ramzi Benamar
Chief Financial Officer
Biolinq Inc · Form D, Mar 21, 2025
DB
David Berry
Director
DR
Derek Rapp
Director
ZB
Zina Besse
Director
RY
Richard Yang
Executive officer and director
TJ
Thad Johnson
Director
JT
Jared Tangney
Executive officer
DB
Dan Bradbury
Director
DA
David Arida
Executive officer
HistoSonics, Inc. · Form D, Aug 15, 2024
FJ
Fred Lee, Jr.
Director
GB
Gerry Brunk
Director
WC
Wen Chen
Director
MB
Michael Blue
Executive officer and director
VK
V. Kadhiresan
Director
TT
Tom Tefft
Director
ER
Erica Rogers
Director
JA
James Adox
Director
Alto Neuroscience, Inc. · Form D, Nov 27, 2023
CC
Christopher Cox
Director
ML
Michael Liang
Director
AW
Aaron Weaver
Director
AD
Andrew Dreyfus
Director
NS
Nicholas Smith
Executive officer
GY
Gwill York
Director
AS
Adam Savitz
Executive officer
PC
Po Yu (Jeff) Chen
Director
AE
Amit Etkin
Chief Executive Officer and director
Lenz Therapeutics, Inc. · Form D, Mar 10, 2023
ES
Evert Schimmelpennink
President & CEO, director
JM
James McCollum
Director
CO
Clare Ozawa
Director
ZS
Zach Scheiner
Director
SL
Stefan Larson
Director
FG
Frederic Guerard
Director
Sources
- SECMoonwalk Biosciences, Inc. Form D, filed Sep 14, 2026
- SECApnimed, Inc. Form D, filed Mar 27, 2026
- SECBiolinq Inc Form D, filed Mar 21, 2025
- SECHistoSonics, Inc. Form D, filed Aug 15, 2024
- SECAlto Neuroscience, Inc. Form D, filed Nov 27, 2023
- SECLenz Therapeutics, Inc. Form D, filed Mar 10, 2023
- SECForms 3, 4 and 5 filed by Chris Dimitropoulos (SEC filer 2146514)